Vipul Brahmbhatt, MD
Clinical Cardiac Electrophysiology · Johnson City, TNNPI 1679559165
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Medtronic at 48.7% of the total. Reporting peaked in 2019 at $4,624 and has fallen 77.4% since, to $1,044 in 2025.
Across 341 payments — averaging $42.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Abbott$3K
- Boston Scientific$745
- Novartis$734
- AstraZeneca$644
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$443
- plus $2K from 22 others
Across 2 payments — averaging $600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$1K
What the payments were for
- Travel & lodging$7,97655%
- Food & beverage$6,40344%
- Education$1251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 68 | $7,065 |
| Abbott | 35 | $3,043 |
| Boston Scientific | 29 | $745 |
| Novartis | 51 | $734 |
| AstraZeneca | 47 | $644 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 43 | $443 |
| Atricure, Inc. | 7 | $358 |
| ZOLL Respicardia, Inc. | 1 | $163 |
| Elutia, Inc. | 9 | $158 |
| Boehringer Ingelheim | 8 | $140 |
| Amgen | 8 | $129 |
| Philips North America LLC | 1 | $113 |
| Edwards Lifesciences | 1 | $102 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Astellas Pharma US Inc | 1 | $99 |
| Johnson & Johnson | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Pfizer | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $47 |
| Irhythm Technologies, Inc. | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $40 |
| Biotronik Inc. | 1 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Convatec Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 2 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,503 in reported general payments places this provider in the 55th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.
See all clinical cardiac electrophysiology providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 571 | $507,163 |
| XareltoRivaroxaban | 201 | $180,715 |
| EntrestoSacubitril/Valsartan | 122 | $121,172 |
| FarxigaDapagliflozin Propanediol | 79 | $65,014 |
| JardianceEmpagliflozin | 24 | $24,979 |
| Dofetilide | 109 | $18,007 |
| MultaqDronedarone Hcl | 11 | $16,359 |
| Flecainide Acetate | 439 | $15,507 |
| BrilintaTicagrelor | 14 | $12,413 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,385 |
| SotalolSotalol Hcl | 338 | $5,582 |
| Amiodarone Hcl | 266 | $4,189 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 188 | $3,901 |
| Clonidine | 32 | $3,419 |
| Metoprolol Succinate | 299 | $3,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $507,163571 claims |
| Johnson & JohnsonXarelto | $59 | $180,715201 claims |
| NovartisEntresto | $734 | $121,172122 claims |
| AstraZenecaFarxiga, Brilinta | $644 | $77,42793 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $140 | $31,36437 claims |
| Sanofi-aventis U.S. LLCMultaq | $35 | $16,35911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.
Other clinical cardiac electrophysiology in Johnson City
- Vijay RamuJohnson City$13K
- Stephen FahrigNashville$605K
- Gregory BashianNashville$361K
- Harish ManyamChattanooga$265K
- William StevensonNashville$172K
- Sandeep DuggalNashville$151K
- Sean WhalenNashville$149K
- David LanGermantown$134K
- Harikrishna TandriNashville$97K
- Robert PickettNashville$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.